Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
First Patent to be Issued from Among Intradigm's Large Collection of Pending siRNA
PALO ALTO, Calif., May 19 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States pa...
Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
Quark's second siRNA
drug delivered systemically
FREMONT, Calif., June 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc.
today announced that the U.S. Food and Drug Administration (FDA) has
approved the Company's Investigational New Drug (IND) application for its
siRNA drug candidate,...
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
... pipeline, which includes PF-04523655, a synthetic sirna
in Phase II clinical studies licensed by Pfizer in...hthalmology indications, and QPI-1002, a synthetic sirna
in Phase I/II studies for two renal indications. T...uark's clinical studies; a case study on the first sirna
administered systemically to man; and an overview ...
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
QPI-1007 is Quark's first proprietary sirna
drug candidate developed in collaboration with Bio...roperty that gives Quark freedom to operate in the sirna
IP space. Previously announced studies have demons...the therapeutic potential of QPI-1007 -- the first sirna
drug candidate based on our own IP -- as well as o...
Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations
...ial of this technology to deliver actives ranging from small molecules to sirna
to monoclonal antibodies . As sirna
needs to be delivered intracellularly to be effective as a therapeutic, the...
Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
... June 8-10, 2009 in San Francisco, CA. QPI-1002, a sirna
drug candidate being developed by Quark Pharmaceut...icals, Inc. is the first systemically-administered sirna
to enter human clinical trials. The drug is the s... to follow the distribution of fluorescent labeled sirna
in the rat kidney, Prof. Molitoris demonstrated ra...
The future of personalized cancer treatment: An entirely new direction for RNAi delivery
... have developed an efficient system for delivering sirna
into primary cells. The work will be published in ...uccessfully developed a technology that allows for sirna
drug delivery into the entire population of cells,...t fusion protein to enter the cell and deliver the sirna
into the cytoplasm where it specifically targets m...
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
...As. Similar data for QPI-1007, Quark's proprietary sirna
composition, were also reported. QPI-1007 was demo...cord in discovering and advancing industry-leading sirna
product candidates. Our strong position in the RNA...eutical partners, including Pfizer, to advance our sirna
product candidates further towards commercializati...
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
...e into the clinic by early 2010. Mersana's preclinical pipeline also includes proprietary targeting moieties employed with conjugates for delivery of sirna
and anti-cancer agents.
The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemical...
Progress Reported Against Gene Involved in Hepatitis C
...RNAs (siRNAs) to block each of the approximately 21,000 predicted messenger RNA transcripts in the human genome had any effect on HCV replication. The sirna
scan identified 96 genes that appear to play a role in HCV replication, and the researchers took a closer look at several of those genes.
One of th...
siRNA in Medical Technology
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA
FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNA...
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Quark siRNAs Examined Alone and in Combination with Chemotherapy
FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a
development-stage pharmaceutical company discovering and developing novel
RNA interference (RNAi)-based therapeutics, today announced that the
Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy'
NEW ROCHELLE, N.Y., Sept. 2 /PRNewswire/ -- The many recent reports
documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in
animal models of human disease may actually be describing non-specific
therapeutic effects related to the ability of siRNA
to activate an immune
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
- Study Published in Journal Molecular Vision -
- Results Show Good Distribution of Bevasiranib to Retina and RPE Cells after a Single Intravitreal Injection -
MIAMI, June 3 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK )
today announced that a study publ...
Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
Findings Support Gene-Silencing Mechanism and Demonstrate Significant Tumor Growth Inhibition Across Multiple Tumor Models in Mice
PALO ALTO, Calif., April 14 /PRNewswire/ -- Intradigm Corporation, a
leading developer of targeted, systemic RNA interference (RNAi)
therapeutics, today anno...
Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Delivery Systems and Specific Molecular Structures Needed for siRNA
LONDON, April 7, 2008 /PRNewswire/ -- Silence Therapeutics plc
(AIM:SLN) Europe's leading RNAi-focused biotechnology company, today
comments on two recent journal articles: Nature...
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Commences Phase I Clinical Trial of Proprietary siRNA
Molecule in Acute Renal Failure
FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a
development-stage pharmaceutical company focused on discovering and
developing novel RNA interference-based ...
Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Quark Expands Hearing Loss Program With Novel SiRNA
Approaches To Noise- Induced Hearing Loss With Its First Drug Candidate, AHLI-11, For The
Prevention Of Chemotherapy-Induced Hearing Loss In Late Pre-IND Stage
FREMONT, Calif., Sept. 24 /PRNewswire/ -- Quark Pharmaceuticals, Inc.,
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Quark's First Hearing Loss Compound, AHLi-11, Slated for IND Filing By Year- End 2007
FREMONT, Calif., Aug. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a
clinical-stage biopharmaceutical company focused on discovering and
developing novel RNA interference-based...
Calando Pharmaceuticals Publishes the First Non-Human Primate Study
on Targeted, Systemic Delivery of siRNA in National Academy of
PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Calando
Pharmaceuticals, a leading siRNA
therapeutics company and a
majority-owned subsidiary of Arrowhead Research Corporation
(NASDAQ: ARWR) announced the publication in the Proceedings of the
National Academy of Sciences (PNAS), the scientific jo...
siRNA in Biological News
Strong immune response to new siRNA drugs in development may cause toxic side effects
New Rochelle, NY, May 20, 2009Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects. Understanding how siRNA
Previous claims of siRNA therapeutic effects called into question by report in human gene therapy
New Rochelle, NY, September 2, 2008The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA
to activate an immune response, according...
Mechanism for the in-vivo transport of siRNA
It all started with flowers: in the nineties of the last century Norwegian researchers discovered that additional copies of a particular gene in petunias inhibited its activity instead of reinforcing it as had been assumed. A few years later it was found that the mechanism is based on the degrada...
Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
A molecular "off" switch packaged in a tiny sphere penetrates deeply into ovarian cancer tumor cells, stifling a troublesome protein and drastically reducing the size of tumors, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 15 edition of Clinical Cancer Rese...
CSHL researchers explain process by which cells 'hide' potentially dangerous DNA segments
...plex initially gets recruited to the regions at the centromere that are destined to become heterochromatin."
At first, scientists thought that the sirna
molecules acted as guides to recruit RITS. After latching on to the chromatin, RITS was in turn thought to recruit the other components: the enzyme th...
New therapeutic strategy could target toxic protein in most patients with Huntington's disease
... don't know why," Zamore said. That meant a single sirna
could shut off expression in the mutant Huntingti...he most exciting part of the study was finding one sirna
that clearly is the top candidate for a clinical t... approve any trial," he continued.
By adding an sirna
against one of two other common SNPs, Zamore says ...
Ambati study published in PNAS
...d his colleagues found that the new drug modality, sirna
(21-nucleotide small-interfering RNA), is toxic no...ablished animal models of new blood vessel growth, sirna
killed these cells by activating an immune recepto...r with this pharmacologic technique. As a result, sirna
is now recognized as a new class of anti-vascular ...
To fight drug addiction, UB researchers target the brain with nanoparticles
...researchers were successful when they combined the sirna
molecules with gold nanoparticles shaped like rods...alled nanorods.
This may be the first time that sirna
molecules have been used with gold nanorods.
"Wh...aped rather than spherical, thus allowing for more sirna
molecules to be loaded on to their surface. This f...
Compounds could be new class of cancer drugs
...ant to the invasive migration of breast cancer cells in culture using a genetic tool called small interfering RNA (siRNA).
"When we had evidence from sirna
and other methods that blocking PLD resulted in dramatic effects of blocking metastatic invasion of breast cancer cells, we were highly motivated to a...
CSHL researchers map changing epigenetic modifications that enable transposons to run amok
...hanges that occur in immortalized cells."
Epigenetic "restructuring" by sirna
The CSHL researchers find that transposons that have lost heterochromatic marks are no longer associated with sirna
that are 24 nucleotides, or RNA "letters," in length. Rather, these re-acti...
siRNA in Biological Technology
Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
GAITHERSBURG, Md., July 22 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA
therapeutics to treat...
Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Issuance Will Give Company Patents in Each of the Three Critical Areas of RNAi Therapeutic Development
PALO ALTO, Calif., March 17 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the United States Pate...
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL )
announced today the global release of MISSION(R) In VIVO QUALITY and iScale
Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA
expected to allow researchers to successfully take the next step in ...
Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
GAITHERSBURG, Md., Oct. 28 /PRNewswire/ -- Sirnaomics, Inc.
(http://www.sirnaomics.com ) announced today that the company has received an SBIR
(small business innovation research) grant from National Cancer Institute
(NCI), National Institute of Health (NIH). Sirnaomics, Inc., a
M. D. Anderson Automates Laboratory Workflow with Stone Bond Technologies : EE-LIMS™ from Stone Bond Technologies Will Document Activities within the Laboratory Workflow at the siRNA Facility, Increasing Throughput, While Reducing Risks
The newly established Small Interfering Ribonucleic Acid (siRNA) Facility at M. D. Anderson Cancer Center has been charged with providing high-quality siRNA
screening services for both internal and external customers.
HOUSTON (Business Wire EON) July 1, 2008 -- M. D. ...
FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry
Quark Pharmaceuticals to develop drug candidate for prevention and treatment of delayed graft function in kidney transplantation
LONDON, June 25 /PRNewswire/ -- Silence Therapeutics plc (London AIM:
SLN) today announces that the U.S. Food and Drug Administration (FDA) has
approved a Qua...
Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
LONDON, March 13 /PRNewswire-FirstCall/ -- Silence Therapeutics plc
(AIM: SLN) today announces a collaboration with AstraZeneca (LSE: AZN),
focused on the development of a range of novel approaches for the delivery
molecules. The deal builds on Silence Therapeutics' leading
Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
ROCKVILLE, Md., Dec. 26 /PRNewswire/ -- Sirnaomics, Inc. announced
today that the company has received funding from a variety of Government
Programs. Sirnaomics, Inc. (http://www.sirnaomics.com ), a biopharmaceutical
company founded in early 2007, dedicates to advancing RNA interference
Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
BOULDER, Colo., Nov. 12 /PRNewswire/ -- Aktiv-Dry LLC has been awarded
an SBIR research grant from the Center for Disease Control and Prevention
(CDC) to explore the formulation of certain siRNA
products as inhalable dry
powders that might eventually be used to treat pulmonary disorders such a...
Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
ST. LOUIS, Oct. 18 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq:
SIAL) announced today the global release of the N-TER(TM) Nanoparticle
siRNA Transfection System. N-TER allows researchers to reproducibly
interrogate gene function, via siRNA
transfection, in model cell types that
siRNA in Biological Products
siRNA in Biological Dictionary
Small interfering RNA ( siRNA
), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA
... RNA interference (RNAi) is a system within living cells ...
...osystems - Cell Transfection Resource ... Transient and Stable Transfection . Cancer Cell Lines and Primary Cells. RNA Interference (RNAi) ... sirna
Transfection ... ALTOGEN® Transfection Reagents have been developed and ... for siRNA-induced studies where transient modification of gene ...
...) ... Transfection reagents are highly efficient for plasmid DNA and sirna
... Transfection is the transient or stable introduction of exogenous mol...specialized transfection reagents that effectively deliver plasmid DNA, sirna
or duplex RNAi, oligonucleotides, and RNA into eukaryotic cells for a ......
... intramolecular reaction, ... Thus, RNA splicing actually helps multicellular organisms to economize in ... posted to transcription splicing sirna
silencing regulation gene alternative by ... Deep surveying of alternative splicing complexity in the human transcriptome by ... Incorpora...
...... Choose Tools > Shotgun Cloning ... General Cloning . General Expression. Inducible Protein ... Shotgun Cloning . Sequencing. Shuttle. sirna
(Gene Silencing) Two-Hybrid. Other. Vector Construction ... Shotgun , cloning ,biological ,biology dictionary,biology terminology,biology terms,bi...
... purine ... molecule of claim 1, wherein the sense strand includes a terminal cap moiety at ... ( A) Base pair homology comparison of 736 sirna
sense strand with TNFR1 mRNA. ... 736 SENSE STRAND ACTIVITY IS INHIBITED BY CHEMICAL AND SEQUENCE MODIFICATION ... ...
...r genomic and proteomic assays can now look to Thermo Fisher Scientific for sirna
design, chemical modification, and delivery ... RNA interference: A Natu...nce technology. ... RNAi Web Resources. RNAi Companies RNAi Services sirna
Collections and Databases RNAi ... The term RNA interference ( RNAi ...
...ral... RNA interference ( ¦är¦en¦ā ′intər′firəns ) ( cell and molecular biology ) The process by which foreign, double-stranded RNA is sirna
Database and Reagents ... RNA interference refers to the inhibition of gene expression by small double ... use of RNA interference for art...
... RNA POLYMERASE II ... RNA polymerase (thing) by The Alchemist. Tue Jul 03 2001 at 18:25:23 ... Plant Nuclear RNA polymerase IV mediates sirna
and DNA methylation-dependent ... Transcription requires that the RNA polymerase binds to the DNA at specific ... The RNA polymerase adds t...
... Rna - Definition of Rna at Dictionary.com a free online dictionary with ... Custom RNA Synthesis. World's leading Dharmacon custom RNA and sirna
synthesis ... No viral proteins can be made until viral messenger RNA is available. Thus, the nature of the RNA in the virion affects the s...